Should You Buy Ideaya Biosciences Inc (IDYA) Stock After it Is Higher By 20.04% in a Week?

Ideaya Biosciences Inc (IDYA) stock is higher by 20.04% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Ideaya Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IDYA!

See Full IDYA Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With IDYA Stock Today?

Ideaya Biosciences Inc (IDYA) stock is higher by 7.27% while the S&P 500 has fallen -1.07% as of 1:26 PM on Tuesday, Jul 27. IDYA has gained $1.66 from the previous closing price of $22.84 on volume of 422,807 shares. Over the past year the S&P 500 is higher by 35.05% while IDYA has gained 105.54%. IDYA lost -$1.22 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Ideaya Biosciences Inc click here.

More About Ideaya Biosciences Inc

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Click Here to get the full Stock Report for Ideaya Biosciences Inc stock.